Table 1.

Comparison of Induction and Maintenance Dosing for Medications Used Across PsA, Psoriasis, and IBD

	Psoriasis		Psoriatic Arthritis		Inflammatory Bowel Disease
Drug	Induction	Maintenance	Induction	Maintenance	Induction	Maintenance
infliximab	5-10mg/kg IV wks 0,2,6	5-10mg/kg IV q4-8 wks	5-10mg/kg IV wks 0,2,6	5mg/kg IV q8 wks	5-10mg/kg IV wks 0,2,6	5-10mg/kg IV q4-8 wks
adalimumab	80mg SQ single dose (wk 0)	40mg SQ q2 wks (starting wk 1)	N/A	40mg SQ q2 wks	160mg SQ wk 0, 80mg wk 2	40-80mg SQ q1-2 wks
certolizumab	400mg SQ q2 wks	400mg q2 wks SQ; if <90 kg consider 200mg dose	400mg SQ wks 0,2,4	200mg SQ q2 wks	400mg SQ wks 0,2,4	400mg SQ q4 wks
golimumab	N/A	N/A	IV: 2mg/kg wks 0,4 SQ: 50mg qmonth	IV: 2mg/kg q8 wks SQ: 50mg qmonth	200mg SQ wk 0, 100mg wk 2	100mg SQ q4 wks
ustekinumab	<100 kg: 45mg SQ wks 0,4 >100 kg: 90mg SQ wks 0,4	<100 kg: 45mg SQ q12 wks; may require 90mg or q8 wks >100 kg: 90mg SQ q12 wks; may require q8 wks	45mg SQ wks 0,4	45mg SQ q12 wks; may require 90mg or q8 wks	260/390/520mg IV single dose (weight-based)	90mg SQ q8 wks
risankizumab	150mg SQ wks 0,4	150mg SQ q12 wks	150mg SQ wks 0,4	150mg SQ q12 wks	CD: 600mg IV wks 0,4,8 UC: 1200mg IV wks 0,4,8	180 or 360mg SQ q8 wks (starting wk 12)
guselkumab	100mg SQ wks 0,4	100mg SQ q8 wks	100mg SQ wks 0, 4	100mg SQ q8 wks	UC: 200mg IV wks 0,4,8	200mg SQ q4 or 100mg q8 wks
tofacitinib	N/A	N/A	N/A	5mg PO BID or 11mg daily (ER)	10mg PO BID	5-10mg PO BID
upadacitinib	N/A	N/A	N/A	15mg PO daily	CD: 45mg PO daily x12 wks UC: 45mg PO daily x8 wks	15 - 30mg PO daily

Legend: PsA: psoriatic arthritis; IBD: inflammatory bowel disease; q: every; wk(s): week(s); IV: intravenous; SQ: subcutaneous; CD: Crohn’s disease; UC: ulcerative colitis; PO: oral; N/A: not applicable; BID: twice daily; ER: extended-release